PILOT STUDY TO CHARACTERIZE THE COMPOSITION/DIVERSITY OF THE GUT MICROBIOME IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER RECEIVING STANDARD OF CARE CHECKPOINT BLOCKADE IMMUNOTHERAPY

Investigator: Eric Bernicker, MD

Study Coordinator: Lacey Burey

Status: Open Not Enrolling

ClinicalTrials.gov Number: N/A

Phone: 713.441.1159

Protocol Number: Pro00023057

Description

The purpose of this pilot study is to characterize the composition/diversity of the gut microbiome in patients with metastatic NSCLC who are receiving standard of care checkpoint blockade immunotherapy. This study will lay the groundwork for larger studies aimed at investigating the relationship between the gut microbiome and the therapeutic efficacy of checkpoint blockade immunotherapy in NSCLC patients. These studies will be valuable in 1) assessing the utility of specific gut microbiome species as biomarkers for identifying patients who have a greater likelihood of response to checkpoint blockade immunotherapy and 2) developing therapeutic strategies to alter patients’ gut microbiomes to potentiate the efficacy of checkpoint blockade immunotherapy.
More to Explore